Welcome to BioSeeker Group!

Immunotherapy in Oncology Drug Pipeline Update 2012

Additional Information

Published Date Feb 21, 2012
Format Software Application
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

€2,450.00

Quick Overview

BioSeeker Group have identified 469 companies plus partners who are today developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer across 337 different targets. In addition, there are 16 suspended drugs and another 343 drugs where development has been ceased.
Request free sample pages from Immunotherapy in Oncology Drug Pipeline Update 2012

Executive Summary

BioSeeker Group have identified 469 companies plus partners who are today developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer across 337 different targets. In addition, there are 16 suspended drugs and another 343 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Immunotherapy in Oncology Drug Pipeline Update 2012 will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work


Some facts about Immunotherapy in Oncology Drug Pipeline Update 2012

Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.
There are today 469 companies plus partners developing 871 cancer immunotherapy drugs in 1970 developmental projects in cancer. In addition, there are 16 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 343 drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 337 different targets. These targets are further categorized on in the software application by 56 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.


Details from Immunotherapy in Oncology Drug Pipeline Update 2012 at a glance

This short overview shows actual findings from the Immunotherapy in Oncology Drug Pipeline Update 2012 report.

Investigators Includes more than 469 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 871 cancer immunotherapy drugs in development, which have a total of 1970 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 48
Registered# 1
Pre-registration# 5
Phase III# 65
Phase II# 226
Phase I# 227
Preclinical# 601
No Data# 4
Suspended# 16
Ceased# 343

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included cancer immunotherapy drugs are also in development for 186 other indications, where of 84 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Identified drugs are linked to more than 337 different targets, divided into 56 classifications of molecular function:
- Acid phosphatase activity
- Antigen binding
- Auxiliary transport protein activity
- B cell receptor activity
- Carboxypeptidase activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Cofactor binding
- Complement activity
- Cysteine-type peptidase activity
- Cytokine activity
- Defense/immunity protein activity
- DNA binding
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- Extracellular ligand-gated ion channel activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Growth factor activity
- Hormone activity
- Hydrolase activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Metallopeptidase activity
- MHC class I receptor activity
- Molecular function unknown
- Oxidoreductase activity
- Peptidase activity
- Peptide hormone
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Structural molecule activity
- T cell receptor activity
- Transcription factor activity
- Transcription regulator activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Unclassified
- Unknown

Identified targets are categorized into 26 different primary and alternate sub-cellular localizations:
- Apical membrane
- Cell junction
- Cell surface
- Centrosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Extracellular matrix
- Golgi apparatus
- Immunological synapse
- Integral to membrane
- Lysosome
- Mitochondrion
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Plasma membrane
- Secreted
- Secretory granule
- Soluble fraction

Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 397 protein expression profiles of 256 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath.
- BioCarta# 212 Pathways
- KEGG# 113 Pathways
- NetPath# 23 Signaling Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

Immunotherapy in Oncology Drug Pipeline Update 2012 provides you with a profile for each identified drug. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Investigator & Partners Presentation of principal investigator and partners.
Target and Molecular Function of Target Described target(s) is/are presented with:
Official Gene Symbol – Official Gene Name [Species/Homo Sapiens] – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Analysis Business & Markets
Collaborations and deals
Approvals and submissions
Analyst comments
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Preclinical Data Available preclinical development data, developmental history and scientific data.
Licensing Information Availability for licensing.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report selection of drugs that match your criteria.


Application Features Use 13 different parameters, available in drop-down menus, to find and sort among drugs
- Drug status
- Clinical Trial Status
- Principle Investigator
- Partners
- Indication
- Developmental Stage
- Compound Type
- Mechanism
- Target
- Molecular Function of Target
- Target Localization
- Targeted Pathways
- Free text search of entire drug profile contents

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
- Direct links to company web pages of principal investigators

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or an entire search you want have a report of.
System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request free sample pages from Immunotherapy in Oncology Drug Pipeline Update 2012

Other selected research from the 'Drugs' category:


IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 130 companies plus partners who are today developing 157 IL-4 pathway targeting drugs in 409 developmental projects in cancer across 92 different targets. In addition, there are 3 suspended drugs and another 61 drugs where development has been ceased. Learn More


Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


TSH Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 135 companies plus partners who are today developing 182 TSH pathway targeting drugs in 551 developmental projects in cancer across 121 different targets. In addition, there are 2 suspended drugs and another 81 drugs where development has been ceased. Learn More


Liver Cancer Drug Pipeline Update 2012
BioSeeker Group have identified 151 companies plus partners who are today developing 179 drugs targeting liver cancer in development. across 128 different targets. In addition, there are 2 suspended drugs and another 46 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Immunomodulators' category:


Antibodies in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 290 companies plus partners who are today developing 538 antibody drugs in 1245 developmental projects in cancer across 260 different targets. In addition, there are 6 suspended drugs and another 295 drugs where development has been ceased. Learn More


Analytical Tool - Cancer Therapeutic Antibodies
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More